Pfizer: Bull Market vs. Bear Market

  Pfizer: Bull Market vs. Bear Market The pharmaceutical giant has outstripped the market in the past decade, but will the fight against COVID-19 change that? Pharmaceutical heavyweight Pfizer PFE (NYSE) $49,60 -0,05 (-%0,10), headquartered in New York City, is also most recently known for its COVID-19 vaccine, Comirnaty. But what will the vaccine do to reward shareholders as it continues to bring the drugmaker tens of billions of dollars?

Bulls:  billions of dollars in revenue.

Pfizer brought great satisfaction to investors with its Coronavirus vaccine program last year. Billions of dollars in vaccine revenue are reported each quarter. Of course, although Pfizer shares its profits with its biotech partner BioNTech  BNTX (NASDAQ) $258,05 +7,57 (+%3,02), it still leaves the pharmaceutical giant with a significant profit factor. It seems that the number is expected to continue its upward trend as the 2022 order discussions are not over. After all, experts predict that the coronavirus is permanent. It is now known that Pfizer is a leader not only in prevention but also in treatment. Now that it reports positive data from the coronavirus pill clinical trial, it is very close to seeking approval from the US Food and Drug Administration. This could set him new records. The stock is trading around 12x forward earnings estimate. This is considered certain to reward investors with profits.

Pfizer: Bull Market vs. Bear Market

Bears Vaccines will be bought, not shares.

Although Pfizer wowed the medical community last year with its rapid COVID-19 vaccination program, it is argued that it certainly did not affect Wall Street. What happens when all that vaccine revenue slows is being asked. As it is known, Pfizer has many competitors. It should be noted that Pfizer has historically performed below the S&P 500. It makes sense when you consider that the company has not fully delivered financially. Unfortunately, the vaccine maker has struggled to generate revenue outside of COVID-19 over the past decade, and its share price reflected that. But today's valuation is attractive, and as the Bull Market correctly points out, Pfizer has an overflowing pipeline. Therefore, when the disclosed information is verified, it can provide out-of-market returns for shareholders.  

Source: The Motley Fool

You may also be interested in:

No Need to Wait for a Crash to Buy. This Top Stock is already Dropping More than 40%.